Wegovy and Menopause: What the Evidence Actually Says

Does Wegovy actually help with menopause weight gain, or is this just marketing?

A question our prescribers hear most weeks, and it deserves a straight answer. The weight gain many women experience around perimenopause and menopause is real and biologically driven: falling oestrogen alters fat storage, appetite regulation shifts, and muscle mass typically declines. Wegovy (semaglutide 2.4mg) was not trialled specifically in menopausal women as a standalone group, so we cannot quote a figure unique to this population. What we do have is substantial trial evidence, the STEP 1 study, published in the New England Journal of Medicine, showed an average body-weight reduction of around 15% over 68 weeks in adults with obesity or overweight, alongside lifestyle changes. Many participants in that programme were women in their forties and fifties. For a deeper look at how the evidence applies specifically to this life stage, the does Wegovy work for menopause weight gain page covers the clinical picture in more detail.

The mechanism is relevant here. Semaglutide works on GLP-1 receptors that influence appetite and gastric emptying, the same hunger-regulation pathways that declining oestrogen disrupts. That biological overlap is one reason clinicians find it a reasonable option for this group. It is not a guarantee, and it does not replace the lifestyle changes that matter even more during this period. But for women who qualify clinically, it is a licensed, evidence-backed tool.

What does menopause change about whether you can use Wegovy?

Menopause itself does not disqualify you. Eligibility for Wegovy follows the licensed criteria: adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, high cholesterol, or cardiovascular risk. Those conditions become more common after menopause, which means many women in this life stage meet the criteria on that basis alone. The Wegovy for menopause weight loss page outlines how these criteria map onto this population.

What changes is the clinical conversation, not the eligibility gate. Your prescriber will want to know about any cardiovascular history, relevant because heart risk rises post-menopause. Wegovy actually holds a UK licence for reducing major cardiovascular event risk in eligible adults, which is relevant context for some women. You can read more about that on the Wegovy and heart health page. Bone density is another area worth discussing: significant weight loss can reduce bone mass, which is already a concern during the menopausal years. A good prescriber will flag this and may recommend weight-bearing exercise and calcium/vitamin D attention alongside treatment.

What about HRT, can you take both at the same time?

Yes, in most cases, but the form of HRT matters. NHS England guidance advises that women on GLP-1 medicines who use oral HRT tablets should consider switching to transdermal preparations (patches or gels) because the slowed gastric emptying caused by semaglutide can theoretically affect how consistently an oral tablet is absorbed. This is not a hard contraindication; it is a practical consideration to raise with your GP or gynaecologist. If you are already on patches or a gel, there is no equivalent concern. The Wegovy for perimenopause page covers the HRT overlap in more detail, including what to discuss at your next GP review.

The NHS England guidance on weight management injections is worth reading if you want the official framing, it covers contraception, HRT and surgery considerations in one place. The same source is what our prescribers work from when they review your consultation.

What is still uncertain, and who should you talk to?

Honest answer: a lot of what circulates online about Wegovy and menopause overstates what the trials can tell us. We do not have long-term data specifically on bone outcomes, cardiovascular outcomes, or quality-of-life measures in menopausal women treated with semaglutide. Research is ongoing. What we know is that the medicine is licensed, that it works on appetite pathways, and that the weight-related risks it addresses are heightened in this life stage. The uncertainties are real but they are the same uncertainties that apply to GLP-1 treatment in any adult population, not a special menopause danger signal.

Pregnancy is a different matter entirely. Wegovy is not recommended during pregnancy, while breastfeeding, or when trying to conceive. If any of those situations apply to you now or might apply during treatment, discuss contraception and timing with your prescriber before starting. The Wegovy and pregnancy page covers the full guidance on this. For perimenopause specifically, where cycles may be irregular and pregnancy (though less likely) is still possible, effective contraception should be in place. Your GP or a specialist is the right person to plan that alongside any weight management treatment.

If you want to explore whether Wegovy is right for your situation, start your free consultation with our prescribers, who review every case personally. You can also see how Wegovy is priced as a private prescription, or read about our clinical approach if you want to know more about how we work.